Pyxis Oncology (NASDAQ:PYXS – Free Report) had its price objective hoisted by Royal Bank Of Canada from $6.00 to $7.00 in a research note released on Friday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.
PYXS has been the topic of several other reports. Stifel Nicolaus set a $5.00 price target on shares of Pyxis Oncology in a research note on Thursday. Wells Fargo & Company lifted their price objective on shares of Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 9th. Wedbush cut their price objective on shares of Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Friday. HC Wainwright boosted their price objective on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pyxis Oncology has a consensus rating of “Moderate Buy” and an average target price of $8.71.
Check Out Our Latest Stock Analysis on Pyxis Oncology
Pyxis Oncology Price Performance
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities analysts anticipate that Pyxis Oncology will post -1.21 earnings per share for the current fiscal year.
Institutional Trading of Pyxis Oncology
Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in shares of Pyxis Oncology by 22.0% during the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after purchasing an additional 160,300 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in Pyxis Oncology by 14.8% in the third quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock valued at $114,000 after purchasing an additional 6,295 shares in the last quarter. Finally, T3 Companies LLC acquired a new position in Pyxis Oncology in the third quarter valued at about $61,000. 39.07% of the stock is currently owned by institutional investors.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.
Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.
Further Reading
- Five stocks we like better than Pyxis Oncology
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
